Stocks making the biggest moves premarket: U.S. Steel, Roku, Celsius, Sarepta Therapeutics and more

Several companies experienced significant stock movements following various news events: U.S. Steel rose 5% after President Trump approved its merger with Nippon Steel, including a 'golden share' for the U.S. government; Roku gained 8.5% from an exclusive advertising partnership with Amazon; EchoStar surged 40% following reports of Trump's intervention in a spectrum dispute; and Sage Therapeutics soared 35% on news of its acquisition by Supernus Pharmaceuticals for $795 million, while Sarepta Therapeutics plummeted 37% after a second patient death related to its Elevidys gene therapy, leading to halted shipments.

Analysis

The pre-market session reveals significant, company-specific stock movements driven by diverse catalysts. U.S. Steel shares (X) rose 5% following an executive order approving its merger with Nippon Steel, a deal that notably includes a "golden share" granting the U.S. government substantial control, indicating regulatory clearance albeit with a significant government oversight provision. Roku (ROKU) experienced an 8.5% increase after announcing an exclusive advertising partnership with Amazon, set to expand its reach to approximately 80 million U.S. households and bolster its advertising revenue stream. Advanced Micro Devices (AMD) gained over 2% on a Piper Sandler price target upgrade, driven by optimistic forecasts for its AI business following the resolution of China-related charges post-Q3 and heightened investor confidence regarding a key hyperscaler client. EchoStar (SATS) saw a dramatic surge of over 40% based on reports of presidential intervention aimed at resolving a critical spectrum dispute with the FCC, a development vital for the company to avert potential bankruptcy and proceed with its 5G network ambitions. Celsius (CELH) shares climbed approximately 4% after TD Cowen upgraded the stock to "buy," citing renewed growth momentum, strong brand perception, successful integration of the Alani Nu acquisition, and anticipated wider distribution. Victoria's Secret (VSCO) shares added 3% on news that activist investor Barrington Capital Group has acquired a stake, intending to push for board changes and a business refocus. In the biopharmaceutical sector, Sage Therapeutics (SAGE) soared 35% upon agreeing to be acquired by Supernus Pharmaceuticals in a $795 million deal ($12 per share plus a contingent value right), which will diversify Supernus's revenue with the FDA-approved drug Zurzuvae. Conversely, Sarepta Therapeutics (SRPT) plummeted over 37% after reporting a second patient death associated with its Elevidys gene therapy, leading to a halt in product shipments and an urgent focus on improving safety protocols, marking a severe clinical and commercial setback.

Key Decisions for Investors

• Investors should carefully assess the long-term implications of the U.S. government's 'golden share' on U.S. Steel's strategic autonomy post-merger, while Sage Therapeutics shareholders should evaluate the total potential value of the Supernus acquisition, including the milestone-dependent CVR.
• Monitor the execution and monetization of Roku's Amazon advertising partnership and AMD's AI business performance post-Q3 as potential key growth drivers, alongside Celsius's progress in integrating Alani Nu and expanding distribution following its analyst upgrade.
• Approach EchoStar with caution as its significant stock appreciation is based on reports of intervention rather than confirmed resolution of its spectrum dispute, and exercise extreme vigilance with Sarepta Therapeutics due to the material clinical setback and halted shipments for its Elevidys gene therapy.
• Consider the potential for strategic changes and value creation at Victoria's Secret following activist investor Barrington Capital's engagement, while also being mindful of potential increased volatility.